HUE040596T2 - Új terápiás megközelítések CMT és rokon rendellenességek kezelésére - Google Patents

Új terápiás megközelítések CMT és rokon rendellenességek kezelésére

Info

Publication number
HUE040596T2
HUE040596T2 HUE12196650A HUE12196650A HUE040596T2 HU E040596 T2 HUE040596 T2 HU E040596T2 HU E12196650 A HUE12196650 A HU E12196650A HU E12196650 A HUE12196650 A HU E12196650A HU E040596 T2 HUE040596 T2 HU E040596T2
Authority
HU
Hungary
Prior art keywords
related disorders
new therapeutic
therapeutic approaches
treating cmt
cmt
Prior art date
Application number
HUE12196650A
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Oxana Guerassimenko
Serguei Nabirochkin
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of HUE040596T2 publication Critical patent/HUE040596T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
HUE12196650A 2007-11-30 2008-11-28 Új terápiás megközelítések CMT és rokon rendellenességek kezelésére HUE040596T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301614A EP2065038A1 (en) 2007-11-30 2007-11-30 New therapeutic approaches for treating Charcot-Marie-Tooth disease
US99180007P 2007-12-03 2007-12-03

Publications (1)

Publication Number Publication Date
HUE040596T2 true HUE040596T2 (hu) 2019-03-28

Family

ID=39264515

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12196650A HUE040596T2 (hu) 2007-11-30 2008-11-28 Új terápiás megközelítések CMT és rokon rendellenességek kezelésére

Country Status (24)

Country Link
US (6) US8992891B2 (hu)
EP (4) EP2065038A1 (hu)
JP (4) JP5953000B2 (hu)
KR (1) KR101546031B1 (hu)
CN (2) CN101883561B (hu)
AU (1) AU2008328745B2 (hu)
BR (1) BRPI0819678A2 (hu)
CA (3) CA3031490C (hu)
CY (2) CY1113980T1 (hu)
DK (2) DK2609916T3 (hu)
EA (3) EA019402B1 (hu)
ES (3) ES2408785T3 (hu)
HR (2) HRP20130345T1 (hu)
HU (1) HUE040596T2 (hu)
IL (1) IL205741A0 (hu)
LT (1) LT2609916T (hu)
MX (1) MX2010005709A (hu)
NZ (1) NZ585440A (hu)
PL (2) PL2609916T3 (hu)
PT (2) PT2609916T (hu)
SI (2) SI2609916T1 (hu)
TR (1) TR201819564T4 (hu)
WO (1) WO2009068668A1 (hu)
ZA (1) ZA201003610B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
WO2010025322A2 (en) * 2008-08-28 2010-03-04 The Florida International University Board Of Trustees Magnetic nanodelivery of therapeutic agents across the blood brain barrier
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2502079B1 (en) * 2009-11-20 2015-01-28 Pharnext New diagnostic tools for charcot-marie-tooth disease
RU2583926C2 (ru) 2010-01-15 2016-05-10 ИНСЕРМ (Энститю Насьеналь де ла Санте э де ла Решерш Медикаль) Соединения для лечения аутизма
DK2624832T3 (en) * 2010-10-08 2018-01-08 Vib Vzw HDAC INHIBITORS FOR TREATMENT OF CHARCOT-MARIE-TOOTHS DISEASE
CN102464610B (zh) * 2010-11-16 2014-07-30 北大方正集团有限公司 一种美替拉酮的制备方法
JP6133790B2 (ja) * 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
EP2678320B1 (en) 2011-02-23 2018-09-19 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
CN102247324B (zh) * 2011-07-14 2012-11-21 海南美兰史克制药有限公司 一种氟马西尼脂质体注射液
CN102887830B (zh) * 2012-09-04 2013-11-27 苏州弘森药业有限公司 一种盐酸酚苄明的制备方法
US10016142B2 (en) 2012-10-19 2018-07-10 Sidewaystrategies Llc Systems and methods for nerve mapping and monitoring
US20150329483A1 (en) * 2012-12-17 2015-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and Pharmaceutical Compositions for the Treatment of X-Linked Charcot-Marie-Tooth
NZ714684A (en) 2013-06-05 2020-05-29 Pharnext Stable oral solutions for combined api
MX2016010409A (es) 2014-02-11 2016-11-30 Pharnext Combinacion de baclofeno, acamprosato y trigliceridos de cadena media para el tratamiento de trastornos neurologicos.
MX2016010967A (es) * 2014-02-24 2016-11-29 Pharnext Nuevas composiciones para tratar lesiones neuronales mecanicas.
US20160339015A1 (en) * 2015-05-20 2016-11-24 Lupin Inc. Oral pharmaceutical composition of methylergonovine
EP3426349A4 (en) * 2016-03-09 2020-01-01 Ionis Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US11272871B2 (en) 2016-07-14 2022-03-15 Sidewaystrategies Llc System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways
WO2018076060A1 (en) * 2016-10-26 2018-05-03 Genea Ip Holdings Pty Ltd Improved generation of muscle lineage cells and therapeutic uses thereof
RU2020107188A (ru) 2017-07-28 2021-08-30 Эпплайд Терапьютикс Инк. Композиции и способы лечения галактоземии
EP3966320A4 (en) * 2019-05-07 2023-10-25 University of Miami TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS
CA3176768A1 (en) * 2020-05-01 2021-11-04 Shoshana SHENDELMAN Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen
US11523984B1 (en) * 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
WO2023182288A1 (ja) * 2022-03-22 2023-09-28 国立大学法人京都大学 シャルコー・マリー・ツース病の治療または予防薬

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
JP4346817B2 (ja) 1997-09-30 2009-10-21 第一三共ヘルスケア株式会社 経口投与製剤
EP1115864A2 (en) * 1998-09-22 2001-07-18 Incyte Genomics, Inc. Human chaperone proteins
JP2002526417A (ja) * 1998-10-02 2002-08-20 セルトリックス ファーマシューティカルズ，インコーポレイテッド 非甲状腺性疾患の治療方法
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
JP4994570B2 (ja) * 2001-07-04 2012-08-08 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 胃保持制御ドラッグデリバリーシステム
AU2003220290B2 (en) * 2002-03-14 2007-06-14 Euro-Celtique S.A. Naltrexone hydrochloride compositions
US7790215B2 (en) * 2002-03-26 2010-09-07 Purdue Pharma Lp Sustained-release gel coated compositions
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
US7109223B2 (en) 2002-08-28 2006-09-19 Merck & Co. Inc. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
CA2516816C (en) * 2003-02-24 2012-02-07 Pharmaceutical Productions, Inc. Transmucosal drug delivery system
SI1615646T2 (sl) * 2003-04-08 2022-11-30 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije vsebujoče metilnatrekson
CA2522471A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
ATE464049T1 (de) 2003-09-25 2010-04-15 Euro Celtique Sa Pharmazeutische kombinationen von hydrocodon und naltrexon
CA2537029C (en) 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
WO2007134136A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) * 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
ATE511392T1 (de) 2007-01-11 2011-06-15 Xenoport Inc Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
US7806721B2 (en) * 2007-08-02 2010-10-05 Tyco Electronics Corporation Patch panel modular jack assembly
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) * 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
PL2796132T3 (pl) 2011-03-01 2018-10-31 Pharnext Terapia zaburzeń neurologicznych oparta na baklofenie i akamprozacie
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
NZ714684A (en) 2013-06-05 2020-05-29 Pharnext Stable oral solutions for combined api
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
US20180338969A1 (en) 2018-11-29
JP2011504915A (ja) 2011-02-17
CN101883561A (zh) 2010-11-10
SI2211846T1 (sl) 2013-07-31
EA032767B1 (ru) 2019-07-31
ES2703508T3 (es) 2019-03-11
CA2705408A1 (en) 2009-06-04
CA2705408C (en) 2019-04-23
CY1113980T1 (el) 2016-07-27
ES2831855T3 (es) 2021-06-09
US20180360785A1 (en) 2018-12-20
NZ585440A (en) 2011-12-22
PT2609916T (pt) 2019-01-10
EP2609916A1 (en) 2013-07-03
EP2065038A1 (en) 2009-06-03
EP3459535B1 (en) 2020-08-12
LT2609916T (lt) 2019-02-11
US8992891B2 (en) 2015-03-31
EA201791669A3 (ru) 2018-03-30
EP3459535A1 (en) 2019-03-27
HRP20182147T8 (hr) 2019-04-19
CN104257657B (zh) 2017-07-04
US20180250289A1 (en) 2018-09-06
JP2018109043A (ja) 2018-07-12
JP2019142917A (ja) 2019-08-29
JP2016145227A (ja) 2016-08-12
US20200155491A1 (en) 2020-05-21
ZA201003610B (en) 2011-06-29
EP2211846A1 (en) 2010-08-04
HRP20130345T1 (hr) 2013-07-31
EA019402B1 (ru) 2014-03-31
CY1121183T1 (el) 2020-05-29
EA035711B1 (ru) 2020-07-29
CN104257657A (zh) 2015-01-07
CN101883561B (zh) 2014-07-30
ES2408785T3 (es) 2013-06-21
EA201301078A1 (ru) 2014-06-30
EP2609916B1 (en) 2018-11-07
EA201791669A2 (ru) 2017-12-29
CA3031490C (en) 2021-05-04
US20100310641A1 (en) 2010-12-09
PT2211846E (pt) 2013-05-10
US20150157626A1 (en) 2015-06-11
CA3031484A1 (en) 2009-06-04
KR101546031B1 (ko) 2015-08-25
US10322101B2 (en) 2019-06-18
MX2010005709A (es) 2010-11-05
WO2009068668A1 (en) 2009-06-04
PL2211846T3 (pl) 2013-09-30
SI2609916T1 (sl) 2019-03-29
PL2609916T3 (pl) 2019-03-29
JP5953000B2 (ja) 2016-07-13
JP6608309B2 (ja) 2019-11-20
DK2609916T3 (en) 2019-01-21
CA3031484C (en) 2021-05-04
AU2008328745B2 (en) 2014-01-30
DK2211846T3 (da) 2013-04-29
EP2211846B1 (en) 2013-02-27
IL205741A0 (en) 2010-11-30
HRP20182147T1 (hr) 2019-03-08
BRPI0819678A2 (pt) 2017-05-09
US10441558B2 (en) 2019-10-15
CA3031490A1 (en) 2009-06-04
EA201000914A1 (ru) 2010-12-30
AU2008328745A1 (en) 2009-06-04
KR20100088160A (ko) 2010-08-06
TR201819564T4 (tr) 2019-01-21
US10463640B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
HRP20182147T1 (hr) Novi terapijski pristupi za liječenje cmt-a i srodnih poremećaja
HK1259102A1 (zh) 用於治療微生物病症的amp
ZA200900734B (en) Combination treatment for metabolic disorders
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
GB0602178D0 (en) Therapeutic treatment
ZA201003497B (en) Methods for treating obesity and obesity related diseases and disorders
HK1158172A1 (en) Compounds for treating ophthalmic diseases and disorders
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
HK1206590A1 (en) New compositions for treating cmt and related disorders
IL222557A (en) A compound for use in treating mutant disorders has ruled
EP2219448A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
IL201422A0 (en) Therapeutic agents useful for treating pain
ZA201002167B (en) Treatment regime for proliferative disorders
GB0608655D0 (en) Therapeutic Treatment
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
EP2120994A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPOGLYKEMIC CONDITIONS
PT2481407T (pt) Compostos para utilização no tratamento de distúrbios cognitivos
GB0610909D0 (en) Therapeutic treatment
GB0702537D0 (en) Treatment for excessive adiposity
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL207906A0 (en) Treatment for ocular-related disorders
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
HK1145282A1 (en) Treatment of sleep disorders
GB0610376D0 (en) Therapeutic treatment